|Bid||38.01 x 800|
|Ask||41.50 x 800|
|Day's Range||38.22 - 39.85|
|52 Week Range||26.95 - 55.00|
|Beta (3Y Monthly)||0.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||52.50|
Ideally, your overall portfolio should beat the market average. But even the best stock picker will only win with some selections. At this point some shareholders may be questioning theirRead More...
Pacira Pharmaceuticals, Inc. (PCRX) today announced new data showing that a patient-optimizing, opioid-sparing enhanced recovery after surgery (ERAS) pathway, which includes intraoperative infiltration with EXPAREL® (bupivacaine liposome injectable suspension), results in high rates of early discharge and patient satisfaction among Medicare-insured patients undergoing total knee or hip arthroplasty (TKA or THA). The research was detailed during a podium presentation at the American Academy of Orthopaedic Surgeons (AAOS) 2019 Annual Meeting in Las Vegas. Retrospective chart review data were captured for 645 consecutive Medicare patients who underwent primary inpatient TKA (337 patients) or THA (308 patients) between June 1, 2015, and November 16, 2017.
Pacira Pharmaceuticals Inc NASDAQ/NGS:PCRXView full report here! Summary * Bearish sentiment is low and declining Bearish sentimentShort interest | PositiveShort interest is low for PCRX with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 15. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold PCRX had net inflows of $1.56 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
A new report found that only 28 percent of startups have at least one woman on the founding team and only 40 percent have at least one woman on the board of directors. Here's more on that and other midweek venture and startup news from the Bay Area.
NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Myoscience’s purchase will generate returns for Accuitive Medical Ventures, Valiance Asset Management and other investors in the company. Myoscience formed in 2005 and raised a total of about $175 million in venture capital, according to Timothy Still, who became Myoscience chief executive last year. Myoscience developed the iovera system, which applies intense cold to targeted nerves.
Shares of Pacira Pharmaceuticals Inc. fell 1.9% in premarket trade Tuesday after the company announced it was planning to acquire MyoScience Inc., a privately-held company that markets an FDA-approved non-opioid treatment for pain associated with osteoarthritis and knee replacement surgery. MyoScience's therapy, called Iovera, is a device that delivers doses of cold temperature to targeted nerves, which temporarily stops those nerves from sending pain signals -- a technique known as cryoanalgesia. Pacira thinks combining Iovera with its own drug Exparel -- a local anesthetic made up of bupivacaine and liposome delivery system DepoFoam -- could have the additive effect of getting patients off opioids entirely during post-surgical recovery. "By combining Iovera with Exparel, we are offering healthcare providers an effective, non-opioid multimodal regimen that can help mitigate or even eliminate the use of opioids for managing pain before, during and after surgery," said Pacira Chief Executive Dave Stack in a statement. Under the terms of the agreement, Pacira will make an initial payment of $120 million, and MyoScience shareholders could receive up to an additional $100 million upon achievement of certain regulatory and commercial milestones. The deal is expected to close in April. Pacira said it plans to change its corporate name to Pacira BioSciences, Inc., while MyoScience will become Pacira CryoTech, Inc. Shares of Pacira have gained 28% in the year to date, while the S&P 500 has gained 2.6%. "By combining Iovera with Exparel, we are offering healthcare providers an effective, non-opioid multimodal regimen that can help mitigate or even eliminate the use of opioids for managing pain before, during and after surgery," said Pacira Chief Executive Dave Stack in a statement. Under the terms of the agreement, Pacira will make an initial payment of $120, and MyoScience shareholders will be eligible to receive up to an additional $100 million upon achievement of certain regulatory and commercial milestones. The deal is expected to close in April. Pacira said it will change its corporate name to Pacira BioSciences, Inc., while MyoScience will become Pacira CryoTech, Inc. Shares of Pacira have gained 28% in the year to date, while the S&P 500 has gained 2.6%.
Pacira Pharmaceuticals, Inc. (“Pacira”) (PCRX) and MyoScience, Inc. (“MyoScience”), a privately held medical technology company, today announced the signing of a definitive agreement for the acquisition of MyoScience by Pacira. MyoScience currently markets the ioveraº system, a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specific nerve to interrupt its ability to transmit a pain signal.
-- Increasing adoption of EXPAREL® Across Opioid-Sparing Pain Management Protocols -- -- EXPAREL net product sales expected to be in the range of $400M to $410M in 2019 -- --.
PARSIPPANY, N.J., Feb. 21, 2019 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2018 financial.
Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Herbalife (HLF) is likely to gain from its direct-selling network, product portfolio and solid volumes. However, unfavorable currency movements and stiff competition may hurt the bottom line.
Pacira Pharmaceuticals, Inc. (PCRX) today announced that commercial production of EXPAREL® (bupivacaine liposome injectable suspension) is now underway at a custom suite in Swindon, UK created under the company’s partnership with Thermo Fisher Scientific Pharma Services (formerly Patheon UK Limited). This first suite was designed to mirror the company’s existing facility at the Pacira Science Center Campus in San Diego, CA and is expected to double the company’s manufacturing capacity. Through the partnership, the companies are developing a second dedicated suite that is expected to enable another doubling of EXPAREL manufacturing capacity in approximately two years. “Launching this new manufacturing site marks an important milestone for Pacira and advances our commitment to providing an opioid alternative to as many surgical patients as possible,” said Dave Stack, chairman and chief executive officer of Pacira.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Anyone researching Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) mightRead More...
Pacira Pharmaceuticals, Inc. (PCRX) today announced that its Phase 4 study of EXPAREL® (bupivacaine liposome injectable suspension) in patients undergoing Cesarean section (C-section) achieved its primary endpoint with a statistically significant reduction in total postsurgical opioid consumption through 72 hours (P≤0.05). EXPAREL also achieved statistical significance for reduction in pain intensity scores through 72 hours (P≤0.05).